Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs

Syndax Pharmaceuticals (NASDAQ:SNDX) is one of the best cancer stocks to invest in now. On February 15, at the Guggenheim biotech conference, Chief Executive Officer Michael Metzger reiterated that Syndax Pharmaceuticals (NASDAQ:SNDX) started 2026 on a strong footing, going by the commercial performance of two key marketed products. In addition, the company is making significant progress on clinical and lifecycle milestones. Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key ...